Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entera BioENTX 29 EV-to-OCF is -45.11 as of Aug. 18, 2026. GuruFocus rates ENTX with a GF Score™ of 29/100. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Entera Bio ranks better than 91.06% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Entera Bio's Enterprise Value is $491.23 Mil.
Entera Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-10.89 Mil. Therefore, Entera Bio's EV-to-OCF for today is -45.11.
The historical rank and industry rank for Entera Bio's EV-to-OCF or its related term are showing as below:
ENTX'
s EV-to-OCF Range Over the Past 10 Years
Min: -45.67 Med: -3.9 Max: -0.02
Current: -45.11
During the past 11 years, the highest EV-to-OCF of Entera Bio was -0.02. The lowest was -45.67. And the median was -3.90.
ENTX's EV-to-OCF is ranked better than 91.06% of 1409
companies
in the Biotechnology industry
Industry Median: -3.6
vs ENTX: -45.11
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Entera Bio's share price for today is $2.90.
Entera Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Entera Bio EV-to-OCF Related Terms
Entera Bio EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Entera Bio's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entera Bio's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Entera Bio's EV-to-OCF falls into.
Entera Bio's current Enterprise Value is $491.23 Mil.
Entera Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio (ENTX) has a EV-to-OCF of -45.11 as of Aug. 18, 2026. According to the industry distribution chart, Entera Bio ranks #126 out of 1409 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Entera Bio's EV-to-OCF too high?
Entera Bio's current EV-to-OCF is -45.11. Based on the distribution chart, Entera Bio ranks #126 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Entera Bio has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's EV-to-OCF compare to ICCC and BDTX?
According to the Biotechnology industry distribution chart, Entera Bio ranks #126 out of 1409 companies for EV-to-OCF. This places Entera Bio in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Entera Bio's current EV-to-OCF is -45.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current EV-to-OCF of -45.11. The current EV-to-OCF is -45.11. Entera Bio's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Entera Bio (ENTX), the current EV-to-OCF is -45.11 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
29GF Score
Get the complete analysis for ENTX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTX has been successfully added to your 
